Home Agilent Technologies

Agilent Technologies

    Agilent Technologies Announces Expanded Use for PD-L1 IHC 28-8 pharmDx Diagnostic in Europe

    Approved for Use in Europe to Identify Head and Neck Cancer Patients Most Likely to Benefit from Opdivo (nivolumab) Therapy Agilent Technologies Inc. (NYSE: A)...

    RECENT COMMENTS